drugset / Trial / NCT03482180

Evaluate the Efficacy and Safety of KI1106 in Patients Whose TG Level is Not Adequately Controlled With Atorvastatin Calcium Monotherapy While LDL-C is Properly Controlled

NCT03482180 ↗

Phase 3 Completed 215 enrolled Kuhnil Pharmaceutical Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

To examine variation rate of Non-HDL with KI1106 comparison Atorvastatin monotherapy.

Timeline

Start
2016-05-04
Primary completion
2017-05-16
Completion
2018-03-23

Drugs

EvaluationDrugModalityDoseRoute
Comparator Atorvastatin Small molecule 20 mg —
Subject KI1106 Unknown 4 g —

Indications